Osteoarthritis (OA) of the knee Musculoskeletal Diseases Gonarthrosis
Conditions
Interventions
Current inteerventions as of 14/09/2018:
Three types of care management will be compared:
1. CMP from General Practitioner (GP)
2. CMP alongside a KneeK
Sponsors
École de Technologie Supérieure
University of Montreal Hospital Research Centre (Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM))
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 or over 2. Suffering of OA of the knee as physician-diagnosed according to the criteria of the American College of Rheumatology: The patient has a radiographic knee X-ray confirming the presence of osteoarthritis II, III or IV according to the scale of Kellgren-Lawrence for at least one knee; and at least 1 of the 3 following signs: Age =40; Morning stiffness <30 minutes; Crepitus 3. OA is the leading cause of pain 4. Being able to walk on a treadmill (exclude problem of balance patient who limps, which uses cane or walker). 5. Having experienced as pain worse in the last 7 days for at least one knee, a =4/10 pain intensity on a scale of 0-10, where 0 = 'no pain' and 10 being 'worst possible pain' 6. Being able to read, understand and respond to questionnaires in French 7. Agreeing to participate in the study and sign the consent form
Exclusion criteria
Exclusion criteria: 1. Suffer from secondary OA or inflammatory arthritis (according to Arden 'Best Practice & Research') or ochronosis, acromegaly, hemochromatosis, calcium pyrophosphate arthropathy (MPPC), Marfan syndrome, Ehlers-Danlos syndrome, epiphyseal dysplasia, osteonecrosis/bone infarction, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, reactive arthritis (Reiter's), gouty arthritis, SAPHO syndrome, Paget disease 2. Have seen a specialist (orthopedist, a rheumatologist or specialist in musculoskeletal disorders) in the past for problems with the affected knee 3. Suffer from active cancer (with or without pain) 4. Fracture history or septic arthritis in the knee 5. Pregnant or suspected to be
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase 1: difference between the three groups at 6 months (0 to 6 months) of the variation of the overall score Knee Osteoarthritis Outcome Score (KOOS5) including 5 dimensions Phase 2: difference in direct and indirect costs for the three therapeutic models at 6, 12 and 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 18/09/2018: 1. Difference in joint biomechanics, as measured by KneeKG at 6 months, as defined by the normal to abnormal passage of at least one biomechanical risk factor from the following: 1.1. Absolute difference in biomechanical factors 1.2. Difference in objective functional tests (30-second sit-stand test and quadriceps strength measured with a dynamometer 2. Overall Knee Osteoarthritis Outcome Score (KOOS5) at 12 months Previous secondary outcome measures as of 14/09/2018: Phase 1: difference in joint biomechanics, as measured by KneeKG, between the three groups at 6 months, as defined by the normal to abnormal passage of at least one biomechanical risk factors from the following. Improved absolute different biomechanical factors. Difference in objective functional tests (30 second chair test and quadriceps strength) Comparison of overall score of Knee Osteoarthritis Outcome Score (KOOS5), to 12 months between the three therapeutic models (1- GP group, 2- GP group and KneeKG, 3- GP group with KneeKG and My Osteoarthritis program) Previous secondary outcome measures: Phase 1: difference in joint biomechanics, as measured by KneeKG, between the three groups at 6 months, as defined by the normal to abnormal passage of at least one biomechanical risk factors from the following. Improved absolute different biomechanical factors. Comparison of overall score of Knee Osteoarthritis Outcome Score (KOOS5), to 12 months between the three therapeutic models (1- GP group, 2- GP group and KneeKG, 3- GP group with KneeKG and My Osteoarthritis program) Phase 2: difference at 6, 12 and 24 months in quality of life, knee function, pain and global impression of change | — |
Countries
Canada
Contacts
Public ContactHélène Lanctôt
Outcome results
None listed